Piper Sandler Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM - Free Report) had its price objective cut by Piper Sandler from $70.00 to $55.00 in a report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also recently weighed in on TEM. Bank of America upped their price target on shares of Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday. Guggenheim reissued a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and increased their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC increased their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Finally, JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $61.18.

Remove Ads

Tempus AI Price Performance

TEM stock traded up $0.24 on Tuesday, hitting $49.10. The company's stock had a trading volume of 9,329,504 shares, compared to its average volume of 4,780,820. The firm has a 50 day moving average of $54.02 and a two-hundred day moving average of $52.54. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the sale, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,406,855 shares of company stock worth $350,610,637 over the last ninety days.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Tempus AI during the fourth quarter valued at about $108,000. Voloridge Investment Management LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at about $11,826,000. Two Sigma Advisers LP bought a new stake in shares of Tempus AI during the fourth quarter valued at about $625,000. ProShare Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at about $244,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at about $1,034,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.